Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 24664760)

1.

Cone specific promoter for use in gene therapy of retinal degenerative diseases.

Dyka FM, Boye SL, Ryals RC, Chiodo VA, Boye SE, Hauswirth WW.

Adv Exp Med Biol. 2014;801:695-701. doi: 10.1007/978-1-4614-3209-8_87.

2.
3.

Restoration of cone vision in a mouse model of achromatopsia.

Alexander JJ, Umino Y, Everhart D, Chang B, Min SH, Li Q, Timmers AM, Hawes NL, Pang JJ, Barlow RB, Hauswirth WW.

Nat Med. 2007 Jun;13(6):685-7. Epub 2007 May 21.

4.

A naturally occurring mouse model of achromatopsia: characterization of the mutation in cone transducin and subsequent retinal phenotype.

Jobling AI, Vessey KA, Waugh M, Mills SA, Fletcher EL.

Invest Ophthalmol Vis Sci. 2013 May 9;54(5):3350-9. doi: 10.1167/iovs.13-11831.

PMID:
23580486
5.

Prospects for retinal cone-targeted gene therapy.

Alexander JJ, Hauswirth WW.

Drug News Perspect. 2008 Jun;21(5):267-71. doi: 10.1358/dnp.2008.21.5.1219012.

PMID:
18596991
6.

Identification of a zebrafish cone photoreceptor-specific promoter and genetic rescue of achromatopsia in the nof mutant.

Kennedy BN, Alvarez Y, Brockerhoff SE, Stearns GW, Sapetto-Rebow B, Taylor MR, Hurley JB.

Invest Ophthalmol Vis Sci. 2007 Feb;48(2):522-9.

PMID:
17251445
7.

Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia.

Kohl S, Baumann B, Rosenberg T, Kellner U, Lorenz B, Vadalà M, Jacobson SG, Wissinger B.

Am J Hum Genet. 2002 Aug;71(2):422-5. Epub 2002 Jun 20.

8.

Achromatopsia as a potential candidate for gene therapy.

Pang JJ, Alexander J, Lei B, Deng W, Zhang K, Li Q, Chang B, Hauswirth WW.

Adv Exp Med Biol. 2010;664:639-46. doi: 10.1007/978-1-4419-1399-9_73.

9.

Gene therapy rescues cone function in congenital achromatopsia.

Komáromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A, Tanaka JC, Acland GM, Hauswirth WW, Aguirre GD.

Hum Mol Genet. 2010 Jul 1;19(13):2581-93. doi: 10.1093/hmg/ddq136. Epub 2010 Apr 8. Erratum in: Hum Mol Genet. 2011 Dec 15;20(24):5024.

10.

Characterization of a transgenic mouse line lacking photoreceptor development within the ventral retina.

Fong SL, Criswell MH, Belecky-Adams T, Fong WB, McClintick JN, Kao WW, Edenberg HJ.

Exp Eye Res. 2005 Oct;81(4):376-88.

PMID:
16054133
11.

Localization of upstream silencer elements involved in the expression of cone transducin alpha-subunit (GNAT2).

Morris TA, Fong WB, Ward MJ, Hu H, Fong SL.

Invest Ophthalmol Vis Sci. 1997 Jan;38(1):196-206.

PMID:
9008644
12.

Targeting gene expression to cones with human cone opsin promoters in recombinant AAV.

Komáromy AM, Alexander JJ, Cooper AE, Chiodo VA, Glushakova LG, Acland GM, Hauswirth WW, Aguirre GD.

Gene Ther. 2008 Jul;15(14):1049-55. doi: 10.1038/gt.2008.32. Epub 2008 Mar 13. Erratum in: Gene Ther. 2008 Jul;15(14):1073. Glushakova, L G [added]. Gene Ther. 2011 Dec;18(12):1179.

13.

Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.

Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, Dejneka NS, Pearce-Kelling SE, Maguire AM, Palczewski K, Hauswirth WW, Jacobson SG.

Mol Ther. 2005 Dec;12(6):1072-82. Epub 2005 Oct 14.

14.

Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2).

Aligianis IA, Forshew T, Johnson S, Michaelides M, Johnson CA, Trembath RC, Hunt DM, Moore AT, Maher ER.

J Med Genet. 2002 Sep;39(9):656-60.

15.

Retinal degeneration in cone photoreceptor cell-ablated transgenic mice.

Ying S, Jansen HT, Lehman MN, Fong SL, Kao WW.

Mol Vis. 2000 Jun 24;6:101-8.

16.

Cone photoreceptor function loss-3, a novel mouse model of achromatopsia due to a mutation in Gnat2.

Chang B, Dacey MS, Hawes NL, Hitchcock PF, Milam AH, Atmaca-Sonmez P, Nusinowitz S, Heckenlively JR.

Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5017-21.

PMID:
17065522
17.

Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy.

Carvalho LS, Xu J, Pearson RA, Smith AJ, Bainbridge JW, Morris LM, Fliesler SJ, Ding XQ, Ali RR.

Hum Mol Genet. 2011 Aug 15;20(16):3161-75. doi: 10.1093/hmg/ddr218. Epub 2011 May 15.

18.

AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia.

Pang JJ, Deng WT, Dai X, Lei B, Everhart D, Umino Y, Li J, Zhang K, Mao S, Boye SL, Liu L, Chiodo VA, Liu X, Shi W, Tao Y, Chang B, Hauswirth WW.

PLoS One. 2012;7(4):e35250. doi: 10.1371/journal.pone.0035250. Epub 2012 Apr 11. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/29fb0ebc-b1c7-4d05-bd70-d29b10299df4.

19.

Genetic etiology and clinical consequences of complete and incomplete achromatopsia.

Thiadens AA, Slingerland NW, Roosing S, van Schooneveld MJ, van Lith-Verhoeven JJ, van Moll-Ramirez N, van den Born LI, Hoyng CB, Cremers FP, Klaver CC.

Ophthalmology. 2009 Oct;116(10):1984-9.e1. doi: 10.1016/j.ophtha.2009.03.053. Epub 2009 Jul 9.

PMID:
19592100
20.

[Gene replacement therapy in achromatopsia type 2].

Mühlfriedel R, Tanimoto N, Seeliger MW.

Klin Monbl Augenheilkd. 2014 Mar;231(3):232-40. doi: 10.1055/s-0034-1368180. Epub 2014 Mar 21. Review. German.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk